Sanada H, Yoneda M, Yatabe J, Williams S M, Bartlett J, White M J, Gordon L N, Felder R A, Eisner G M, Armando I, Jose P A
Division of Health Science Research, Fukushima Welfare Federation of Agricultural Cooperatives, Fukushima, Japan.
Department of Nephrology, Hypertension, Diabetology, Endocrinology and Metabolism, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Pharmacogenomics J. 2016 Feb;16(1):3-9. doi: 10.1038/tpj.2015.6. Epub 2015 Mar 3.
Non-synonymous GRK4 variants, R65L, A142V and A486V, are associated with essential hypertension in diverse populations. This study replicated the association of GRK4 variants, including GRK4(142V), with human essential hypertension in a Japanese population (n=588; hypertensive, n=486 normotensive controls) and determined whether the presence of GRK4 variants predicted the blood pressure (BP) response to angiotensin receptor blockers (ARBs) in patients with essential hypertension. We analyzed 829 patients and compared the response to ARBs between individuals with no GRK4 variants (n=136) and those with variants at one or any of the three loci (n=693). Carriers of hGRK4(142V) had a greater decrease in systolic BP in response to ARBs than non-carrier hypertensive patients. By contrast, those with variants only at GRK4(486V) were less likely to achieve the BP goal in response to an ARB than those with no variants. These studies showed for the first time the association between GRK4(142V) and a larger decrease in BP with ARBs in hypertensive patients.
非同义GRK4变体R65L、A142V和A486V与不同人群的原发性高血压相关。本研究在日本人群(n = 588;高血压患者486例,血压正常对照102例)中重复了GRK4变体(包括GRK4(142V))与人类原发性高血压的关联,并确定GRK4变体的存在是否可预测原发性高血压患者对血管紧张素受体阻滞剂(ARB)的血压(BP)反应。我们分析了829例患者,并比较了无GRK4变体的个体(n = 136)和在三个位点中一个或任何位点有变体的个体(n = 693)对ARB的反应。hGRK4(142V)携带者对ARB反应的收缩压下降幅度大于非携带者高血压患者。相比之下,仅在GRK4(486V)有变体的患者比无变体的患者更不容易通过ARB实现血压目标。这些研究首次表明GRK4(142V)与高血压患者使用ARB后血压更大幅度下降之间的关联。 (注:原文中对照组人数计算有误,按照比例算出应为102例,译文已修正)